scholarly journals Caveolin-1 in Melanoma Progression

10.5772/21829 ◽  
2011 ◽  
Author(s):  
Lorena Lobos-Gonzalez ◽  
Lorena Aguilar ◽  
Gonzalo Fernandez ◽  
Carlos Sanhueza ◽  
Andrew F.G
Keyword(s):  
Caveolin 1 ◽  
Melanoma Progression

1422: Oxytocin Receptor and Caveolin-1 Expression in the Prostate of Young and Aging Male

2005 ◽  
Vol 173 (4S) ◽  
pp. 385-386
Author(s):  
Gregor Bötticher ◽  
Zsófia Herbert ◽  
Erdogan Sendemir ◽  
Andreas Aschoff ◽  
Gustav Friedrich Jirikowski ◽  
...  
Keyword(s):  
Oxytocin Receptor ◽  
Aging Male ◽  
Caveolin 1

Modulation der TGF-β abhängigen CTGF Induktion durch Caveolin-1 in Hepatozyten

2009 ◽  
Vol 47 (09) ◽  
Author(s):  
C Meyer ◽  
C Stump ◽  
A Müller ◽  
S Dooley
Keyword(s):  
Caveolin 1

Caveolin-1 Deficiency Protects Pancreatic ß Cells against Palmitate-Induced Dysfunction and Apoptosis

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 84-OR
Author(s):  
WEN ZENG ◽  
KUNYING LIU ◽  
JIANSONG TANG ◽  
HAICHENG LI ◽  
HAIXIA XU ◽  
...  
Keyword(s):  
Caveolin 1

CLINICAL SIGNIFICANCE OF SERUM CAVEOLIN-1 LEVELS IN GASTRIC CANCER PATIENTS

2018 ◽  
Vol 40 (4) ◽  
pp. 323-327 ◽  
Author(s):  
F Tas ◽  
S Karabulut ◽  
K Erturk ◽  
D Duranyildiz
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Histological Grade ◽  
Clinical Importance ◽  
Disease Stage ◽  
Control Group ◽  
Tissue Samples ◽  
Caveolin 1 ◽  
Study Results ◽  
Gastric Cancer Patients

Aim: Caveolin-1 plays a significant role in the pathogenesis of various carcinomas and its expression affects the survival of cancer patients. However, the molecular function of caveolin-1 and its possible clinical importance has remained uncertain in gastric cancer. No clinical trial has examined serum caveolin-1 levels in gastric cancer patients so far, instead all available results were provided from studies conducted on tissue samples. In the current study, we analyzed the soluble serum caveolin-1 levels in gastric cancer patients, and specified its associations with the clinical factors and prognosis. Material and Methods: Sixty-three patients with pathologically confirmed gastric cancer were enrolled into the trial. Serum caveolin-1 concentrations were detected by ELISA method. Thirty healthy subjects were also included in the study. Results: The median age of patients was 62 years, ranging from 28 to 82 years. The serum caveolin-1 levels in gastric cancer patients were significantly higher than those in control group (p < 0.001). The common clinical parameters including patient age, sex, lesion localization, histopathology, histological grade, disease stage, and various serum tumor markers (e.g. LDH, CEA, and CA 19.9) were not found to be associated with serum caveolin-1 levels (p > 0.05). Similarly, no correlation existed between serum caveolin-1 concentration and chemotherapy responsiveness (p = 0.93). Furthermore, serum caveolin-1 level was not found to have a prognostic role (p = 0.16). Conclusion: Even though it is neither predictive nor prognostic, serum caveolin-1 level may be a valuable diagnostic indicator in patients with gastric cancer. Key

Sign in / Sign up

Export Citation Format

Share Document